FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC

On December 12, 2022, the U.S Food and Drug Administration (FDA) granted accelerated approval to adagrasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C—mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

For more information read the FDA announcement.  

Posted 12/13/2022